Female Pattern Hair Loss: An Overview

Minoxidil is the only FDA-approved topical drug for treating male or female pattern hair loss, and other medications like finasteride and dutasteride can also increase hair growth.

This review discusses the current therapeutic options for female pattern hair loss and emphasizes the need for managing patient expectations of permanent regrowth, reporting no new clinical results.

This article reviews the pathophysiology, diagnosis, and treatment of female pattern hair loss, highlighting the importance of early medical intervention to arrest hair loss progression, but reports no new clinical results.

This article reviews the impact of nutritional deficiencies on hair health, detailing how they can cause structural abnormalities, pigmentation changes, or hair loss; it presents no new clinical findings.

This review discusses treatment options for female pattern hair loss, emphasizing the importance of early intervention and the benefits of combined therapies, but reports no new clinical results.

This review discusses various treatments for androgenetic alopecia, including minoxidil, finasteride, dutasteride, ketoconazole, and experimental options, but reports limited clinical trial evidence for efficacy.

This study found that mesotherapy with a dutasteride-containing preparation improved hair growth indicators in female pattern hair loss better than saline, with minimal side effects and greater effectiveness in patients with shorter disease duration.

This study reveals that human hair follicles transition between active and dormant states stochastically, challenging the idea of a cyclical automaton controlling hair growth.

This study reported that trichoscopy is a more effective diagnostic tool than the trichogram for early diagnosis of FAGA, regardless of hair shaft diversity cut-off levels.

This article reviews how chronological aging affects female scalp hair growth and suggests that multiple factors, including environmental influences, contribute to female pattern hair loss; no new clinical results are presented.

This review discusses the influence of menopausal status on hair parameters in women without alopecia, finding significant differences in hair growth rate, percentage anagen, and hair diameter distributions, particularly in the frontal scalp.

This study found that PRP combined with dalteparin and protamine microparticles may enhance hair growth by increasing hair thickness compared to PRP alone.

In this study, latanoprost significantly increased hair density in young men with mild androgenetic alopecia after 24 weeks, suggesting it may stimulate hair follicle activity and treat hair loss.

This review discusses recent surgical and medical advancements in hair restoration techniques but reports no new clinical results.

This study found that a once-daily 5% minoxidil topical foam is as effective as a twice-daily 2% minoxidil topical solution for hair growth in women with androgenetic alopecia, with fewer side effects and greater styling convenience.

This study found that long-term flutamide treatment reduced hair loss in women with female pattern hair loss, but liver-related dropouts were minimized at a very low dose of 62.5 mg/day.

This review explores the current understanding of genetic and hormonal influences on male androgenetic alopecia and female pattern hair loss, providing guidance for clinicians but reports no new results.

In this study, the researchers reported that finasteride's efficacy in treating female pattern hair loss in Japanese patients was not predictable based on CAG repeat numbers in the androgen receptor gene.

This review discusses advancements in the genetic understanding of androgenic alopecia and the FDA-approved treatments, including a new laser hair comb, but reports no clinical results.

This guideline reviews the diagnosis of androgenetic alopecia and offers expert consensus recommendations tailored to males, females, and adolescents, but reports no new clinical results.

This study suggests that 5 mg/day oral finasteride may increase hair density and thickness in normoandrogenic Asian women with female pattern hair loss over 12 months.

This review discusses the safety and efficacy of bimatoprost ophthalmic solution 0.03% for enhancing eyelash growth by influencing the eyelash hair cycle and follicles, and it reports no new results.

This case report describes a patient with complete androgen insensitivity syndrome experiencing female pattern hair loss, suggesting that factors beyond direct androgen action may contribute to this condition in women.

This article reviews current hair loss treatments, proposing a hypothesis that a combination of drugs, supplements, and therapies may effectively manage hair loss, but presents no new clinical results.

In this study, genetic variation in the CYP19A1 gene, particularly the common rs4646 C allele, was associated with an increased risk of female pattern hair loss, especially in women under 40.

This study found that dermoscopy can be a useful tool for diagnosing androgenetic alopecia, particularly in determining hair diameter diversity as an essential feature in Asian populations.

This study found that trichoscopy criteria can distinguish female androgenic alopecia from chronic telogen effluvium, with specific features achieving 98% diagnostic specificity.

This study found that both topical and oral finasteride had similar therapeutic effects in treating male androgenic alopecia, with no significant differences in hair thickness, counts, or bald area size.

This study found that the HairMax LaserComb® significantly increased hair density and was safe and well tolerated for treating androgenetic alopecia in men compared to a sham device.

This review discusses hair transplant techniques for female pattern hair loss and reports no new clinical results; it highlights the benefits of transplants combined with various treatments for improved hair density and styling options.

This review discusses the various treatment options for male and female pattern hair loss and provides no new clinical results; the authors outline the most effective strategies based on existing evidence.

This review discusses the role of androgens in hair follicle regulation and suggests that a better understanding could enhance treatments for conditions like hirsutism and alopecia, but does not present new findings.

This study found that topical fulvestrant did not significantly improve hair growth parameters in men and postmenopausal women with androgenetic alopecia, unlike minoxidil, which was more effective in men.

This study found that a new 5% minoxidil foam formulation significantly increased hair counts and improved hair loss condition in men with androgenetic alopecia over 16 weeks compared to placebo.

This study found that 1% topical minoxidil significantly increased hair count and improved hair growth perception among Japanese women with androgenetic alopecia compared to placebo.

This article introduces the term "anisotrichosis" to describe the significant variation in hair shaft diameters observed in pattern alopecia, drawing a parallel to anisocytosis seen in blood smears, but reports no new research findings.

This case report describes how a 53-year-old woman with female pattern hair loss experienced further hair regrowth when topical minoxidil was added to her spironolactone treatment after initial results plateaued.

This review discusses female pattern hair loss, highlighting that while oral antiandrogens and topical minoxidil can arrest progression, early diagnosis and treatment are crucial, and stresses the need for ongoing therapy.

This study found that as hair loss severity increased in women with female pattern hair loss, the number of vellus follicles also rose, indicating miniaturization of terminal hair follicles.

This study observed that 62% of premenopausal women with female pattern hair loss reported improvement when treated with oral finasteride and an oral contraceptive containing drospirenone and ethinyl estradiol.

In this case study, significant improvement in androgenic alopecia was observed in a 46-year-old woman after 9 months of treatment with dutasteride following limited success with finasteride.

This study found that the prevalence of androgenetic alopecia increases with age among both men and women in Maryborough, Australia, with 57% of women and 73.5% of men aged 80 and over affected.

In this case series, researchers observed androgenetic alopecia in 20 prepubertal children with a strong genetic predisposition, despite the condition typically not occurring before puberty.

This study found that 88% of women with female pattern hair loss who received oral antiandrogens saw no progression or improvement in their condition.

This review discusses the role of estrogens in hair follicle cycling and the skin, highlighting the need for more research on estrogen signaling pathways and their interactions with other factors in hair biology.

This article reviews pharmacologic treatments for pattern hair loss and emphasizes integrating them with surgical and nonmedical options, but it does not present new clinical findings.

In this 48-week trial, 5% topical minoxidil was more effective than both 2% minoxidil and placebo in promoting hair growth in women with female pattern hair loss, with notable improvements in nonvellus hair count and hair growth assessments.

This article reviews the mechanisms by which minoxidil stimulates hair growth and reports no new clinical findings.

This study found that peripilar signs on the scalp are linked to perifollicular lymphocytic infiltrates in early androgenetic alopecia, detectable even in areas with high hair density.

This paper suggests that ketoconazole 2% shampoo may enhance finasteride's effectiveness in treating androgenetic alopecia by more completely inhibiting the dihydrotestosterone pathway.

This article explains why modern hair transplant techniques can be effective for women with pattern hair loss, despite this being underrecognized.

This study reports that oral finasteride improved or stabilized hair loss in women with hyperandrogenism but not in postmenopausal women with female pattern hair loss.

Hair loss in women is genetic, diagnosed by examination and biopsy, and treated with minoxidil, finasteride, or transplantation.

This study reported that while finasteride and progesterone significantly inhibited dihydrotestosterone synthesis in dermal papillae, estrogens were less effective.

This study proposes a new clinical scoring method for hair density based on hair diameter diversity, which correlates with existing measures and reflects follicle miniaturization in androgenetic alopecia.

This article discusses treatment approaches for female pattern hair loss and concludes that available medical treatments are effective in reversing or stabilizing the condition in most cases of mild-to-moderate severity.

Genes and hormones cause hair loss, with four genes contributing equally.

FPHL affects hair density and diameter, causing visible hair loss in older women.

Hair loss in women is common, starts in late 20s, and affects 30% of women over 50.

In this study, finasteride 1 mg/day for 12 months did not improve hair growth or slow hair thinning in postmenopausal women with androgenetic alopecia compared to placebo.

This study reported that finasteride 1 mg/day significantly increased hair growth and slowed hair loss in men with frontal scalp hair thinning over one year, and these benefits continued or improved in the second year.

People with hair loss have more androgen receptors and enzymes in certain follicles, with men and women showing different patterns.

This study found that 2% topical minoxidil solution was significantly more effective than placebo in promoting new hair growth in women with androgenetic alopecia.

This study found that androgenetic alopecia causes significant psychological distress, particularly in women, who exhibit a more negative body image and less adaptive functioning compared to controls.

This study found that minoxidil 2% increased nonvellus hair counts in women with female androgenetic alopecia without causing serious side effects, compared to a placebo.

Diffuse alopecia in women may be related to androgens and iron deficiency, and basic hormone and nutrient screening is useful.

This article presents a classification system for stages of female-pattern androgenetic alopecia to aid early diagnosis and mentions existing systems for rare male-pattern cases, but reports no new clinical results.